Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by nitazoxanide: an effect independent of spike variants emergence

Riccio, Anna; Santopolo, Silvia; Rossi, Antonio; Piacentini, Sara; Rossignol, Jean-Francois; Santoro, M. Gabriella

doi:10.1007/s00018-022-04246-w

Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by nitazoxanide: an effect independent of spike variants emergence

Original Article
Open access
Published: 07 April 2022

Volume 79, article number 227, (2022)
Cite this article

Download PDF

You have full access to this open access article

Cellular and Molecular Life Sciences Aims and scope Submit manuscript

Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by nitazoxanide: an effect independent of spike variants emergence

Download PDF

Anna Riccio¹^na1,
Silvia Santopolo¹^na1,
Antonio Rossi²,
Sara Piacentini¹,
Jean-Francois Rossignol³ &
…
M. Gabriella Santoro ORCID: orcid.org/0000-0003-1432-4949^1,2

2870 Accesses
15 Citations
11 Altmetric
1 Mention
Explore all metrics

This article has been updated

Abstract

SARS-CoV-2, the causative agent of COVID-19, has caused an unprecedented global health crisis. The SARS-CoV-2 spike, a surface-anchored trimeric class-I fusion glycoprotein essential for viral entry, represents a key target for developing vaccines and therapeutics capable of blocking virus invasion. The emergence of SARS-CoV-2 spike variants that facilitate virus spread and may affect vaccine efficacy highlights the need to identify novel antiviral strategies for COVID-19 therapy. Here, we demonstrate that nitazoxanide, an antiprotozoal agent with recognized broad-spectrum antiviral activity, interferes with SARS-CoV-2 spike maturation, hampering its terminal glycosylation at an endoglycosidase H-sensitive stage. Engineering multiple SARS-CoV-2 variant-pseudoviruses and utilizing quantitative cell–cell fusion assays, we show that nitazoxanide-induced spike modifications hinder progeny virion infectivity as well as spike-driven pulmonary cell–cell fusion, a critical feature of COVID-19 pathology. Nitazoxanide, being equally effective against the ancestral SARS-CoV-2 Wuhan-spike and different emerging variants, including the Delta variant of concern, may represent a useful tool in the fight against COVID-19 infections.

Spike mutation D614G alters SARS-CoV-2 fitness

Article 26 October 2020

Imatinib inhibits SARS-CoV-2 infection by an off-target-mechanism

Article Open access 06 April 2022

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Article Open access 30 March 2020

Introduction

Human coronaviruses (HCoV) were discovered in the 1960s and were originally thought to cause only mild upper respiratory tract diseases in immunocompetent hosts, with several strains being responsible for the common cold [1,2,3]; however, public awareness of HCoV has changed considerably since the beginning of this century, with the SARS (Severe Acute Respiratory Syndrome) epidemic in 2002 and the MERS (Middle East Respiratory Syndrome) outbreak in 2012, two zoonotic CoV infections that resulted in mortality rates of approximately 10% and 35%, respectively [4].

Near the end of 2019, the seventh human coronavirus, phylogenetically in the SARS-CoV clade (lineage B) and, therefore, named SARS-CoV-2, emerged in China [5]. SARS-CoV-2 turned out to be a far more serious threat to public health than SARS and MERS HCoVs because of its ability to spread more efficiently than its predecessors, making it difficult to contain worldwide, and causing an unprecedented global health crisis, as well as societal and economic disruption. The clinical features of the disease associated with SARS-CoV-2 infection, COVID-19 (coronavirus disease-2019), vary ranging from asymptomatic state to respiratory symptoms that, in a subset of patients, may progress to pneumonia with massive alveolar damage and extreme rise in inflammatory cytokines production that may lead to acute respiratory distress syndrome (ARDS), thrombosis, multi-organ dysfunction and death [5, 6].

SARS-CoV-2 infection is initiated by the binding of the spike (S) glycoprotein to the host receptor, which, similarly to SARS-CoV, is the human angiotensin-converting enzyme 2 (hACE2) [7,8,9]. The spike protein, together with the M (membrane) and E (envelope) proteins, is anchored into the viral envelope, decorating the virion surface as a distinctive crown (“corona”) (Fig. 1A), and is essential for viral entry into target cells [7, 8].

Similarly to other viral fusion glycoproteins, including influenza hemagglutinin (HA) and parainfluenza fusion (F) proteins, the SARS-CoV-2 spike is a trimeric class-I fusion protein; each monomer is synthesized as a fusogenically inactive precursor of about 180 kDa containing an N-terminal signal peptide (SP) (Fig. 1B) that primes the nascent polyprotein for import into the endoplasmic reticulum (ER), where the protein is extensively modified with N-linked glycans (each protomer comprises 22 N-linked glycosylation sequons) [10, 11]. The spike protein assembles into an inactive homotrimer, which is endoproteolytically cleaved by cellular proteases giving rise to a metastable complex of two functional subunits: S1 (bulb) containing the receptor-binding domain (RBD) responsible for recognition and attachment to the host hACE2 receptor, and the membrane-anchored S2 (stalk) that contains the fusion machinery (Fig. 1B). S2 harbors the fusion peptide (FP), a short segment of 15–20 conserved mainly hydrophobic amino acids, which anchors to target membranes and plays an essential role in mediating membrane fusion by disrupting and connecting lipid bilayers of host cells. The FP is followed by two heptapeptide repeat sequences HR1 and HR2, the transmembrane anchor domain (TM), and a short cytoplasmic tail (CT) (Fig. 1B) [9].

S glycoproteins passing the quality control mechanisms of the ER are transported to the ER/Golgi intermediate compartment (ERGIC), the presumed site of viral budding [12]. Glycosylation plays an essential role in establishing viral spike proteins bioactive conformation and stability, for shaping viral tropism and has effects on virus antigenic properties, receptor binding and fusion activity [10, 13, 14].

Triggering of SARS-CoV-2 S fusion activity is a multistep process that requires sequential cleavage at distinct sites, including, in addition to the canonical CoV cleavage site at the S1/S2 boundary, an S2' site located immediately upstream of the fusion peptide (Fig. 1B). In the case of SARS-CoV-2 an unexpected polybasic furin-like cleavage site (FCS), harboring multiple arginine residues, located at the S1/S2 boundary was shown to be processed during S protein biogenesis for S protein “priming” [7, 15, 16]. Similar cleavage sites have been found in MERS-CoV, but not in other lineage B βCoVs, including SARS-CoV; importantly, the acquisition of similar cleavage sites is associated with increased pathogenicity in other viruses such as avian influenza viruses [17], and it is suggested to be responsible for SARS-CoV-2 high infectivity and transmissibility [7, 15].

Whereas the S1/S2 boundary site is cleaved by furin during biosynthesis in the host cell, the S2′ site cleavage occurs during infection and requires target cell proteases. RBD engagement by the ACE2 receptor exposes the spike S2′ site that can be cleaved by the transmembrane protease, serine 2 (TMPRSS2) at the cell surface (entry by fusion) or by cathepsin L in the endosomal compartment following clathrin-mediated endocytosis [16]. In both cases, release of the fusion peptide triggers the formation of a fusion pore allowing virus entry [16].

Like other enveloped viruses, SARS-CoV-2 infection causes the display of newly synthesized fusogenic S protein on the host cell plasma membrane, which, as discussed later, allows ACE2-expressing neighboring cells to fuse into giant multi-nucleated cells (syncytia) [15, 16].

The SARS-CoV-2 spike glycoprotein is also the primary target of host immune defenses and it is, therefore, the focus of vaccine development [18, 19]. At present, in parallel with a major vaccination endeavor, widespread whole genome sequencing efforts have allowed researchers to track the spread of different lineages globally, identifying several SARS-CoV-2 spike mutations that, providing fitness advantages, facilitate a rapid spread of the virus, also creating great concern on whether some variants may affect the efficacy of recently developed vaccines [20,21,22,23].

Therefore, in addition to prophylaxis, antiviral therapeutics remain urgently needed to combat SARS-CoV-2 in the current pandemic.

Nitazoxanide (NTZ), a thiazolide originally developed as an antiprotozoal agent and used in clinical practice for treatment of infectious gastroenteritis [24, 25], has emerged as a new broad-spectrum antiviral drug [26, 27]. We have previously reported that NTZ and its active circulating-metabolite tizoxanide (TIZ) are effective against different RNA viruses including influenza and parainfluenza viruses, hepatitis C and rotavirus infection in vitro [28,29,30,31], as well as in clinical studies [32,33,34]. Interestingly nitazoxanide was also found to be effective against different animal and human coronaviruses, including MERS-CoV [26, 35, 36] and, more recently, SARS-CoV-2 in vitro [37,38,39] and in COVID-19 patients [39,40,41,42].

While the molecular mechanism of its broad-spectrum antiviral activity has not been fully elucidated, NTZ was shown to inhibit the replication of influenza and parainfluenza viruses by a novel mechanism, impairing terminal glycosylation and intracellular trafficking of the class-I viral fusion glycoproteins influenza hemagglutinin and paramyxovirus F spike proteins [28, 29]. We, therefore, explored the possibility that NTZ may also affect SARS-CoV-2 spike maturation, which is critical for SARS-CoV-2 host recognition, penetration and pathogenesis [11]. Herein we report that nitazoxanide interferes with SARS-CoV-2 S glycoprotein biogenesis, hampering its maturation at an endoglycosidase H (Endo-H)-sensitive stage, and hindering fusion and syncytium-forming ability of the original Wuhan-spike, as well as the Alpha, Beta, Gamma and Delta S-variants in human cells.

Results

Characterization of furin-dependent cleavage of SARS-CoV-2 S protein in human lung cells

Because of its fundamental role in virus infectivity and transmission, the SARS-CoV-2 spike protein structure and function have been extensively studied [7, 10, 43]; however, little is currently known about the SARS-CoV-2 S (SARS-2 S) biogenesis and maturation pathway.

In order to characterize SARS-CoV-2 S synthesis, oligomerization and furin-mediated cleavage as compared to SARS-CoV and MERS-CoV spike proteins in human lung cells, we have utilized two different expression plasmids, containing the full-length SARS-CoV-2 spike gene ORF untagged (VG40589-UT, SARS-2 S) or harboring an antigenic tag (Flag) at the C-terminal (VG40589-CF, SARS-2 S-CF), as well as two plasmids containing the full-length human SARS coronavirus (VG40150-CF) and MERS coronavirus (VG40069-CF) spike proteins both harboring a Flag-tag at the C-terminal.

We first asked whether SARS-2 S is robustly expressed in human lung alveolar type II-like epithelial A549 cells, as compared to human HEK293T cells, commonly used for experimentation because of their high transfectability; we also analyzed whether there is evidence for proteolytic processing of the S protein in lung cells, since it has been shown that SARS-2 S is cleaved by host cell proteases at the S1/S2 cleavage site in HEK293T cells [8].

Immunoblot analysis of A549 cells expressing the untagged SARS-2 S protein revealed a band with a molecular weight of 180 kDa expected for unprocessed S protein (S0) (Fig. 1C); a band with a size expected for the spike S1 subunit (∼ 110 kDa) [44] was also observed at all times tested. In addition to A549 cells, similar results were obtained in human normal lung MRC-5 fibroblasts (Fig. 1D). In A549 cells expressing the SARS-2 S protein with a C-terminal antigenic tag, in addition to the unprocessed S0, a band with a size expected for the S2 subunit (∼ 90 kDa) [45] was also observed when anti-Flag antibodies were utilized (Fig. 1E). These results suggest efficient proteolytic processing of SARS-2 S protein during biogenesis in human pulmonary cells, in keeping with the presence of several arginine residues at the S1/S2 cleavage site.

To confirm the involvement of furin in S protein processing during biogenesis, we analyzed whether the furin irreversible inhibitor decanoyl-RVKR-CMK (RVKR) blocks SARS-2 spike protein processing in our model. As shown in Fig. 1F–H, RVKR inhibited SARS-2 S processing in a concentration-dependent manner, confirming that the SARS-CoV-2 spike cleavage is mediated by furin; RVKR also inhibited the processing of MERS S protein, which is known to depend on furin [46], while it had no effect on SARS S protein expression (Fig. 1I), as expected.

It is interesting to note that inhibition of furin activity by RVKR did not prevent SARS-2 spike trimerization (Fig. 1H), indicating that S1/S2 cleavage is not required for oligomerization in lung cells.

Nitazoxanide alters SARS-CoV-2 S protein biogenesis in human cells

We have previously shown that nitazoxanide (NTZ, Fig. 2A) inhibits the replication of influenza and parainfluenza viruses by impairing terminal glycosylation and intracellular trafficking of the class-I viral fusion glycoproteins influenza hemagglutinin and paramyxovirus fusion spike proteins [28, 29]. To investigate whether NTZ may also affect SARS-CoV-2 spike glycoprotein expression, human lung (A549 and MRC-5), colon (HCT116), liver (Huh7) and kidney (HEK293T) cells were transiently transfected with the SARS-2 S or SARS-2 S-CF plasmids and, after 4 h, were treated with different concentrations of NTZ (Fig. 2B). As shown in Fig. 2C and Fig. S1A, NTZ did not inhibit S protein expression and did not interfere with the S1/S2 cleavage; however, treatment with NTZ at concentrations higher than 0.1 µg/ml caused an evident alteration in the molecular mass of both the S0 precursor and the S1/S2 subunits. This effect persisted for at least 24 h (Fig. S1B) with no change in cell viability, as shown by MTT assay (NTZ LD₅₀ > 50 µg/ml). Interestingly NTZ treatment provoked a similar alteration of SARS-CoV and MERS-CoV spike glycoproteins exogenously expressed in A549 cells (Fig. 2D). Notably, the NTZ-mediated spike alteration was not affected by the presence of single and/or multiple mutations in the S protein, including the aspartic acid-to-glycine substitution at position 614 (D614G) (Fig. 2E), an S protein globally predominant mutation that was found to promote SARS-CoV-2 transmission in humans [47], and the N501Y, E484K and K417N mutations (Fig. S2A) that have been recently described in the B.1.1.7, P.1 and B.1.351 variants being monitored (VBMs) (https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html).

In addition, similar results were obtained using plasmids encoding the Alpha B.1.1.7 (UK), Beta B.1.351 (South Africa) and Gamma P.1 (Brazil) VBMs, and the Delta B.1.617.2 variant of concern (VOC) spike glycoproteins exogenously expressed in A549 cells (Fig. 2F). Finally, it should be noted that, in addition to human cells, nitazoxanide was found to affect SARS-CoV-2 spike biogenesis also in monkey (Vero E6), rodent (murine L929 fibroblasts) and bat lung epithelial cells Tb-1 Lu cells (Fig. S1C–E), indicating a general effect on mammalian cells.

The NTZ-induced alteration in the S glycoprotein electrophoretic mobility pattern was mimicked by the NTZ active metabolite, tizoxanide (Fig. S3A), but not by other antiviral drugs, including chloroquine (10 µM), ribavirin (7.5 µM) and remdesivir (7.5 µM) (Fig. 2G).

Whereas the antiviral activity of nitazoxanide against SARS-CoV-2 replication has been reported in vitro and in clinical settings [37,38,39,40,41,42], the effect of tizoxanide on SARS-CoV-2 infection is not well established. Therefore, the antiviral activity of tizoxanide was examined in a model of SARS-CoV-2 (SARS-CoV-2/England/2/2020) infection in Vero E6 cells. The results, shown in Fig. S3B, demonstrate that the active metabolite of nitazoxanide is effective in inhibiting SARS-CoV-2 replication in vitro with an EC₅₀ of 0.8 µg/ml (2.9 µM) at 24 h post-infection.

Nitazoxanide does not affect SARS-CoV-2 spike stability and oligomerization, but impairs its maturation at an Endo-H-sensitive stage

To investigate whether NTZ treatment affects SARS-CoV-2 S protein stability, A549 cells were transfected with the SARS-2 S construct and treated with NTZ (2.5 µg/ml) for 16 h, at which time protein synthesis was arrested by adding cycloheximide (100 µg/ml). At different times after cycloheximide treatment S protein levels were determined in whole-cell extracts by Western blot and quantitated by scanning densitometry. The results, shown in Fig. 3A, indicate that S protein degradation rate (with a half-life of 7.5 h) is not significantly affected by the thiazolide. Comparable levels of S protein were also detected by confocal microscopy in A549 cells untreated or treated with nitazoxanide (5 µg/ml) for 16 h (Fig. 3B). Notably, nitazoxanide did not prevent the formation of SARS-2 spike dimers and trimers, which, however, were characterized by an evident alteration in electrophoretic mobility, reflecting the monomer modification (Fig. 3C).

Although it is known that glycosylation plays an essential role in establishing coronavirus spike proteins bioactive conformation, stability, tropism and fusion activity [10, 13, 14], presently there is little information on the effect of glycosylation inhibitors on SARS-CoV-2 spike biogenesis. The thiazolide-induced SARS-2 spike alteration was then compared to the effect of the N-glycosylation inhibitor tunicamycin. Interestingly, non-glycosylated spike protein was not detected in the soluble fraction of tunicamycin-treated cells (Fig. S4A, top), an effect that could not be rescued by treatment with the proteasome inhibitor bortezomib [48], suggesting that non-glycosylated proteins are not promptly degraded via ERAD (ER-associated degradation), a sophisticated process for ER-to-cytosol dislocation and ubiquitin/proteasome-mediated degradation of target proteins [49]. In fact, immunomicroscopy studies revealed the formation of large S protein aggregates in tunicamycin-treated cells (Fig. S4B); in addition, the presence of a low-molecular weight band, corresponding to the non-glycosylated spike protein (∼ 130 kDa), was detected in the insoluble fractions of tunicamycin-treated cell lysates (Fig. S4A, bottom). Similar results were previously reported for the spike protein of transmissible gastroenteritis virus (TGEV) CoV [50].

Glycosylation of coronavirus S proteins, like other cell surface glycoproteins, is initiated in the endoplasmic reticulum, adding the “high mannose” oligosaccharides; the mannose-rich sugar component is processed in the Golgi apparatus, and terminal glycosylation occurs in the trans cisternae of the Golgi apparatus [51].

We have previously shown that nitazoxanide blocks the maturation of the influenza virus hemagglutinin at a stage preceding resistance to digestion by endoglycosidase H (Endo-H), an enzyme that removes N-linked carbohydrate chains that have not been terminally glycosylated (Fig. 3D) [52], thus impairing HA intracellular trafficking [28]. To obtain insights on the effect of NTZ on SARS-2 S maturation, we, therefore, investigated whether nitazoxanide could affect S protein terminal glycosylation. SARS-CoV-2 S protein aliquots from NTZ-treated or control cells were subjected to digestion with Endo-H or with PNGase-F, an enzyme that removes all N-glycans [53], up to 6 h after cycloheximide treatment and then analyzed by immunoblot. As expected, S proteins from both untreated and NTZ-treated cells were sensitive to PNGase-F digestion (Fig. 3E). On the other hand, a fraction (approximately 42–43% between 1 and 6 h after cycloheximide treatment) of the SARS-CoV-2 S protein was found to be terminally glycosylated becoming Endo-H-resistant in control cells under the conditions described; notably, S protein from NTZ-treated cells remained instead sensitive to digestion with the glycosidase up to 22 h after synthesis (Fig. 3E). Since acquisition of Endo-H resistance is a marker for transport into the cis and middle Golgi compartments [52], these results indicate that nitazoxanide, as in the case of influenza HA [28], may impair S protein trafficking between the ER and the Golgi complex. Confocal immunomicroscopy analysis using the ER-resident molecular chaperone calnexin as the ER-marker in fact revealed that the spike protein was largely localized in the ER of NTZ-treated cells (Fig. 3B). Of note, treatment with nitazoxanide did not significantly alter the expression of calnexin or other ER proteins, including calreticulin, ERp57, ERp72 and the ER-stress regulated protein GRP78, suggesting that the drug is not triggering the host ER-stress response (Fig. 3F). It should also be noted that, at the effective concentration, nitazoxanide does not alter the expression of the other SARS-CoV-2 structural proteins N, M and E when expressed alone (Fig. S5A) or in combination (Fig. S5B). It is important to note that the presence of large amounts of the nucleocapsid, envelope and in particular the membrane protein, which is known to interact with the S glycoprotein [54], did not prevent the NTZ-induced spike alteration (Fig. S5B).

Finally, the thiazolide-induced SARS-2 spike alteration was also compared to the effect of different glycoprotein maturation inhibitors, including the α-glucosidases inhibitor castanospermine, the ER-Golgi protein trafficking inhibitor brefeldin A, and the mannosidase-I inhibitors deoxymannojirimicin (DMJ) and kifunensine, which was recently shown to alter SARS-CoV-2 spike processing and infectivity [55]. As shown in Fig. S4C, D, neither α-glucosidases nor mannosidase inhibitors caused an alteration in molecular mass comparable to nitazoxanide, suggesting a different activity of the drug. Interestingly, brefeldin A treatment, contrary to nitazoxanide, inhibited S protein cleavage (Fig. S4C).

These results indicate that, as in the case of influenza HA and parainfluenza fusion proteins, nitazoxanide treatment results in hampering SARS-CoV-2 spike maturation.

Nitazoxanide treatment prevents SARS-CoV-2 S pseudovirions infection

Since biochemical assays using purified viral components do not provide insights on the S protein function as it occurs on the virion membrane, we engineered pseudotyped retroviral (Murine Leukemia Virus, MLV) as well as third-generation lentiviral (pLV) particles to express the full-length SARS-CoV-2 S protein together with a luciferase (LUC) or green fluorescent protein (GFP) reporter to monitor infection (Fig. 4A).

SARS-CoV-2 S-pseudotyped particles were generated in producer HEK293T cells treated with different concentrations of nitazoxanide or control diluent for 48 h and then used to infect different types of cells, including monkey Vero E6 cells, that are commonly used in the study of SARS-CoV-2 entry due to their high susceptibility to infection, as well as human airway epithelial Calu-3 cells and intestinal epithelial Caco-2 cells, which both express the ACE2 receptor on their apical surface [56]; in addition, as HEK293T cells were not susceptible to infection by SARS-CoV-2 S-pseudotyped viruses [45], we generated HEK293T cells stably expressing the human ACE2 receptor (293T hACE2 cells) for these studies.

As shown in Fig. 4, nitazoxanide treatment caused the expected SARS-CoV-2 spike alteration in HEK293T producer cells (Fig. 4B, C) and resulted in a dramatic decrease of both MLV (Fig. 4D) and pLV (Fig. 4E) SARS-CoV-2 S-pseudotyped particles infectivity in all cell lines examined, as determined quantitatively by luciferase levels detection. Similar results were obtained when HEK293T producer cells were treated with the NTZ metabolite tizoxanide (Fig. S3C, D).

A marked decrease in infectivity of pseudovirions containing NTZ-modified proteins was also assessed qualitatively by fluorescence microscopy in 293T hACE2 cells infected with GFP-expressing SARS-CoV-2 S-pseudotyped LV particles (Fig. 4F). Similar results were obtained when GFP-expressing SARS-CoV-2 S-pseudotyped LV particles were used to infect Caco-2 hACE2 cells, intestinal epithelial cells engineered to express high levels of the human ACE2 receptor (Fig. S6).

Nitazoxanide inhibits SARS-CoV-2 S-mediated cell–cell fusion and syncytia formation

Besides fusion mediated by virions, SARS-CoV-2 S proteins present at the plasma membrane, contrary to the S protein of the related coronavirus SARS-CoV [57], can trigger receptor-dependent formation of syncytia, which have been observed not only in cell cultures but also in tissues from individuals infected with SARS-CoV-2 [15, 58].

To address the question whether the alteration in SARS-CoV-2 S glycoprotein maturation observed in nitazoxanide-treated cells may affect cell–cell fusion and syncytia formation, we utilized two different approaches.

In the first approach monkey Vero E6 cells and human Huh7 cells, both naturally expressing ACE2 receptors on the membrane surface, transiently transfected with the Flag-tagged SARS-CoV-2 or SARS-CoV (Huh7) spike plasmids were treated with nitazoxanide or vehicle, and processed for immunofluorescence microscopy using an anti-Flag antibody to visualize syncytia formation after 36 h. Consistently with previous reports [57], expression of the SARS-CoV S glycoprotein did not cause syncytia formation in the absence of trypsin in ACE2-expressing Huh7 cells, whereas SARS-CoV-2 spike expression resulted in the formation of large multi-nucleated syncytia in the same model (Fig. 5A). Interestingly, treatment with nitazoxanide, whereas it did not inhibit SARS-CoV-2 spike expression, markedly decreased the number and size of syncytia in both Vero E6 cells (Fig. 5B) and Huh7 cells (Fig. S7), indicating that nitazoxanide may prevent SARS-CoV-2 S-mediated fusion between adjacent cells (fusion 'from within').

In a second type of approach, we investigated whether the drug may prevent cell–cell fusion between different cell types. HEK293T cells were co-transfected with plasmids encoding the Flag-tagged SARS-CoV-2 S glycoprotein and GFP and, after 4 h, treated with nitazoxanide or vehicle (Fig. 5C). At 40 h post-transfection cells were detached and overlaid on an 80% confluent monolayer of target Vero E6 and Huh7 cells at a ratio of approximately one S-expressing cell to three receptor-expressing cells. After 4 h, co-cultures were processed for fluorescence microscopy to visualize syncytia formation, and the extent of cell–cell fusion was determined as described [59]. As shown in Fig. 5D, E, also in this case treatment with nitazoxanide markedly decreased the number and size of syncytia in both Vero E6 cells (Fig. 5D) and Huh7 cells (Fig. 5E), confirming that nitazoxanide may prevent SARS-CoV-2 S-mediated fusion between different types of cells.

Formation of syncytia by pneumocytes expressing SARS-CoV-2 RNA and S proteins was observed post-mortem in lung tissues of COVID-19-infected patients [58]. We, therefore, investigated whether nitazoxanide treatment may prevent SARS-CoV-2 S-mediated fusion in human lung alveolar type II-like A549 cells. As these cells are known to possess low levels of ACE2 [8], we generated A549 cells stably expressing the human ACE2 receptor (A549 hACE2 cells) for these studies. As shown in Fig. 6A, exogenous ACE2 expression resulted in a dramatic increase in SARS-CoV-2 S-mediated fusion between adjacent lung cells, confirming the important role of ACE2 in virus-directed syncytia formation. Consistently with the results obtained in other cell types, treatment with nitazoxanide markedly decreased the number and size of syncytia in A549 hACE2 cells (Fig. 6A). Similar results were obtained when A549 hACE2 cells were used as target cells in the cell–cell fusion co-culture model, using HEK293T cells co-transfected with plasmids encoding the Flag-tagged SARS-CoV-2 S glycoprotein and a GFP reporter as donor cells (Fig. 6B). NTZ-induced inhibition of cell–cell fusion was dose-dependent, with a > 90% suppression of syncytia formation at the concentration of 10 µg/ml (Fig. S8A).

It is known that the SARS-CoV-2 E and M proteins regulate processing and intracellular trafficking of the S glycoprotein, interfering with syncytia formation [54, 60, 61]; we, therefore, investigated whether co-expression of the structural proteins N, M and E with the spike glycoprotein would affect the ability of the drug to inhibit S-mediated cell–cell fusion. As shown in Fig. S5C, the presence of the N, M and E proteins did not prevent cell–cell fusion and did not hinder the ability of nitazoxanide to suppress syncytia formation in lung cells.

These results confirm that SARS-CoV-2 S protein possesses high fusogenic activity and is able to trigger large syncytia formation in human lung cells, and indicate that the alteration in SARS-CoV-2 S glycoprotein maturation observed in nitazoxanide-treated cells impairs spike-driven cell–cell fusion and syncytia formation.

Nitazoxanide inhibits the fusogenic activity of SARS-CoV-2 spike variants

Although coronaviruses are thought to mutate at a slower rate than most RNA viruses due to the presence of a unique viral proofreading machinery [1, 62], CoVs can also undergo recombination events [63]. A meta-analysis of genomes of SARS-CoV-2 strains found several mutations within the virion spikes circulating in a considerable percentage of the analyzed populations [21,22,23]. The most common mutation, now found in most of the global population, is an aspartic acid-to-glycine substitution at position 614 (D614G) in the S1 subunit of the spike protein [47]. The D614G S mutation has been shown to promote SARS-CoV-2 transmission in humans and to enhance functional S protein incorporation into SARS-CoV-2 virus-like particles and pseudovirus particles, increasing pseudovirions infectivity [64].

To investigate whether nitazoxanide treatment was equally effective in inhibiting the infectivity of the SARS-CoV-2 D614G spike variant, we utilized the pCAGGS-SARS2-S-D614 S (wild type, SARS-2 D614) plasmid and the pCAGGS-SARS2-S-G614 S plasmid carrying the D614G mutation (SARS-2 G614), both containing a C-terminal antigenic Flag-tag, to engineer pseudotyped lentiviral particles expressing the full-length SARS-CoV-2 S protein together with a LUC reporter. SARS-CoV-2 D614G S-pseudotyped particles were generated in producer HEK293T cells treated with nitazoxanide (2.5 µg/ml) for 48 h and then used to infect 293T hACE2 cells and intestinal epithelial Caco-2 hACE2 cells.

As shown in Fig. 7A, nitazoxanide treatment caused the expected SARS-CoV-2 D614G spike alteration in HEK293T producer cells and resulted in a dramatic decrease of SARS-CoV-2 D614G S-pseudotyped particles infectivity in both 293T hACE2 and Caco-2 hACE2 cells (Fig. 7B).

Next, human lung A549 hACE2 cells were transfected with the Flag-tagged SARS-CoV-2 D614 or G614 spike plasmids, treated with nitazoxanide or vehicle, and processed for immunofluorescence microscopy using an anti-Flag antibody to visualize syncytia formation after 36 h. As shown in Fig. 7C, expression of the SARS-CoV-2 G614 S glycoprotein was markedly more effective in causing the formation of large multi-nucleated syncytia in lung cells as compared to the wild-type protein. Treatment with nitazoxanide was found to significantly decrease the number and size of syncytia caused by the SARS-CoV-2 G614 spike variant (Fig. 7C).

Similar results were obtained when A549 hACE2 cells were used as target cells in the fusion co-culture model described above, using HEK293T cells co-transfected with plasmids encoding the SARS-CoV-2 S D614 or G614 spike variant together with a GFP reporter as donor cells (Fig. 7D). In addition to the G614 spike variant, nitazoxanide was found to significantly decrease the number and size of syncytia caused by SARS-CoV-2 spike proteins carrying single or multiple mutations including the N501Y, E484K and K417N substitutions (Fig. S2B, C) that, as indicated above, have been recently described in the B.1.1.7, P.1 and B.1.351 VBMs.

In the last year, the variants that have major global health impact include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) VBMs and Delta (B.1.617.2) VOC variants. We, therefore, investigated whether nitazoxanide was effective in inhibiting the infectivity of these SARS-CoV-2 S variants. We utilized the EX-CoV242-M39 (Alpha), EX-CoV244-M39-GS (Beta), EX-CoV245-M39-GS (Gamma) and pCMV3-SARS-CoV-2-Spike (S1 + S2)-long(B.1.617.2) (Delta) plasmids to engineer pseudotyped lentiviral particles expressing the full-length SARS-CoV-2 S proteins together with a LUC reporter, as reported above. SARS-CoV-2 Alpha, Beta, Gamma and Delta S-pseudotyped particles were generated in producer HEK293T cells treated with nitazoxanide (2.5 µg/ml) for 48 h and then used to infect Caco-2 hACE2 cells. As shown in Fig. 8, nitazoxanide treatment resulted in a dramatic decrease in the infectivity of all SARS-CoV-2 S-pseudotyped particles (Fig. 8A–D, I).

Next, we investigated the ability of nitazoxanide to prevent syncytia formation induced by the Alpha, Beta, Gamma and Delta variants. HEK293T cells were co-transfected with the plasmids of interest and GFP and, after 4 h, treated with nitazoxanide or vehicle. At 40 h post-transfection, cells were overlaid on target A549 hACE2 cells monolayers, and processed for fluorescence microscopy to visualize syncytia formation, as described above. As shown in Fig. 8E–I, all spike variants were able to cause cell–cell fusion, and treatment with nitazoxanide markedly decreased the number and size of syncytia in lung cells. As shown above, NTZ-induced inhibition of syncytia formation was dose-dependent (Fig. S8).

Altogether, these results indicate that nitazoxanide is effective in inhibiting cell–cell fusion and syncytia formation mediated by different SARS-CoV-2 spike variants and in different types of cells.

Discussion

As of 28 February 2022, SARS-CoV-2 virus infections have caused more than 437 million confirmed cases and over 5.9 million deaths (https://coronavirus.jhu.edu/map.html) worldwide, wreaking havoc on global public health and economy. Given the proportion of the COVID-19 pandemic and the rise in the associated global death toll, major efforts have been directed over the past months towards a global vaccination plan (https://cdn.who.int/media/docs/default-source/immunization/covid-19/strategy-to-achieve-global-covid-19-vaccination-by-mid-2022.pdf?sfvrsn=5a68433c_5). At the same time, the emergence of several SARS-CoV-2 spike variants that facilitate virus spread and may affect the efficacy of recently developed vaccines [20,21,22,23], together with the short-lasting protective immunity typical of HCoV [65], creates great concern and highlights the importance of identifying antiviral drugs to reduce SARS-CoV-2-related morbidity and mortality. Considerable efforts have been directed over the past months towards the concept of repurposing FDA-approved drugs that have the potential to greatly accelerate clinical availability by eliminating extensive safety testing required for novel drugs. So far, only the RNA-dependent RNA polymerase (RdRp) inhibitor remdesivir has been approved by health authorities for coronavirus infections [66], whereas a different RdRp inhibitor, molnupinavir [67], was approved by MHRA (Healthcare products Regulatory Agency) in the UK (https://www.gov.uk/government/news/first-oral-antiviral-for-covid-19-lagevrio-molnupiravir-approved-by-mhra). Very recently the U.S. Food and Drug Administration also issued an emergency use authorization for Paxlovid (SARS-CoV-2 3CL protease inhibitor co-packaged with ritonavir for oral use) (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19).

Nitazoxanide has been used for decades in medical practice as a safe and effective antiprotozoal drug [24, 25]. As described above, nitazoxanide has been proven to have a broad-spectrum antiviral activity in laboratory settings, as well as in clinical studies that have shown that the drug is effective against rotavirus, hepatitis C, and influenza A and B virus infections [26,27,28,29,30,31,32,33,34].

In the case of Coronaviridae, nitazoxanide is effective against several animal and human strains, including the MERS-CoV in cell culture [26, 35, 36]. As for SARS-CoV-2, at an early stage of the pandemic, Wang et al. reported that nitazoxanide inhibits SARS-CoV-2 replication in Vero E6 cells at low-µM concentrations (EC₅₀ = 2.12 μM) [37]; these observations were recently confirmed in different types of cells, including human lung-derived Calu-3 cells [38, 39]. More importantly several studies have recently shown an antiviral activity and clinical benefits of nitazoxanide in COVID-19 patients [39,40,41,42]. In particular, a recent multicenter, randomized, double-blind, placebo-controlled trial has shown that a 5-day oral treatment with nitazoxanide (600 mg twice daily) prevents the progression to severe respiratory symptoms and hospitalization when administered to patients in the early stages of SARS-CoV-2 infection [42].

While the molecular mechanism of its broad-spectrum antiviral activity has not been fully elucidated, nitazoxanide acts through a cell-mediated mechanism [26, 27] and, in the case of influenza and parainfluenza viruses, it was shown to impair terminal glycosylation and intracellular trafficking of the class-I viral fusion glycoproteins influenza hemagglutinin and paramyxovirus fusion spike proteins [28, 29]. This effect has been previously associated to the drug-mediated inhibition of ERp57, an ER-resident glycoprotein-specific thiol-oxidoreductase which is essential for correct disulfide-bond architecture of selected viral proteins [29].

We now show that nitazoxanide selectively interferes with SARS-CoV-2 S glycoprotein biosynthesis, while it does not affect the expression of the other SARS-CoV-2 structural proteins N, E and M. We find that, as in the case of influenza and parainfluenza fusion proteins, nitazoxanide hampers the spike protein maturation at an Endo-H-sensitive stage, thus preventing its final processing, and resulting in inhibition of the S glycoprotein fusion activity during entry, as well as of syncytia formation due to S-driven cell–cell fusion. The role of the thiol-oxidoreductase ERp57 in the nitazoxanide-induced inhibition of SARS-CoV-2 spike protein maturation is presently under investigation.

The bioactive NTZ metabolite tizoxanide was found to be equally effective in preventing SARS-CoV-2 spike maturation and syncytium-forming ability, hindering viral entry in SARS-CoV-2 S-engineered pseudovirions infection models, and inhibiting infectious SARS-CoV-2 virus propagation in Vero E6 cells with an EC₅₀ of 0.8 µg/ml (2.9 µM). It is important to note that concentrations of tizoxanide of 2–60 µg/ml were found to be achieved in the plasma of patients treated with 300–600 mg nitazoxanide twice daily for 5 days in a randomized double-blind, placebo-controlled phase 2B study in adults and adolescents with acute uncomplicated influenza [33].

Since its emergence, the ancestral Wuhan strain has evolved rapidly, originating several variants harboring multiple mutations, including mutations in the spike protein, which may result in the ability to evade part of the neutralizing antibody response [21,22,23]. We found that nitazoxanide ability to interfere with the S glycoprotein maturation is independent of the spike variants, being equally effective against the original Wuhan-spike as well as the Alpha, Beta, Gamma and Delta spike variants in human cells. This is in line with the cell-mediated mechanism of action previously reported for NTZ [26,27,28,29], and represents an advantage as compared to virus-targeted drugs, considering the continuous emergence of SARS-CoV-2 variants and the CoV ability to undergo recombination events [63]. Interestingly, NTZ was also found to interfere with the maturation of the spike proteins of the human alpha coronavirus 229E and beta coronavirus OC43, causing a remarkable decrease in infectious progeny production in human cells (Piacentini S. et al., manuscript in preparation), and confirming a general effect of the drug against diverse human coronaviruses.

The ability of SARS-CoV-2 S protein to mediate fusion between the viral particle and the cellular membranes during virus entry has been largely studied and documented; however, there is recent evidence that the spike protein is also responsible for fusion of infected cells with neighboring uninfected cells [59, 68]. This process, known as ‘fusion from within’, is mediated by newly synthesized S protein reaching the cell surface, fusing with receptor-positive adjacent cells, and causing the formation of giant multi-nucleated cells (syncytia). Cell–cell fusion is used by different viruses, including the Pneumovirus RSV (Respiratory Syncytial virus), the measles virus (MV) [69] and the human immunodeficiency virus (HIV) [70], to spread in a particle-independent way and promoting immune evasion [71].

Utilizing two different quantitative assays relying on the biogenesis of expressed S protein, we now confirm that the SARS-CoV-2 Wuhan-spike as well as the Alpha, Beta, Gamma and Delta spike variants possess remarkable cell–cell membrane fusion activity, causing syncytia formation in ACE2-expressing cells, and demonstrate that nitazoxanide is effective in inhibiting syncytia formation mediated by the different spike variants in different types of cells. During the preparation of the present manuscript, the Omicron variant emerged and was recently classified as a new VOC (https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-omicron-variant.html). We are presently investigating the effect of nitazoxanide on the Omicron spike variant.

Syncytia formation has been linked to pathological consequence detectable in various tissues such as lung and brain for MV [72] or lymphoid tissues for HIV [70]. In the case of SARS-CoV-2 infection, syncytia formation has been recently described as a hallmark of advanced lung pathology in patients affected with COVID-19 at a frequency undetected in other lung infections before [58, 73,74,75,76]. In particular, fused pneumocytes expressing SARS-CoV-2 RNA and S proteins were observed post-mortem in lung tissues of 20 out of 41 COVID-19-infected patients, indicating that productive infection leads to syncytia formation [58]. Notably SARS-CoV-2 S-mediated syncytia were suggested to increase viral pathogenicity by destabilizing airway epithelia and creating lesions that may be difficult to repair [75]. Interestingly, it has also been recently shown that, whereas neutralizing antibodies and sera from convalescent patients inhibited SARS-CoV-2 particle–cell fusion with high efficiency, cell–cell fusion was only moderately inhibited, suggesting that syncytia formation during COVID-19 may not be effectively prevented by antibodies [68].

The results described herein suggest that, together with virus-targeting drugs, the host-directed broad-spectrum antiviral drug nitazoxanide, by hampering the spike protein maturation and fusion activity, may represent a readily available useful tool in the fight against COVID-19 infections, inhibiting SARS-CoV-2 replication and preventing spike-driven syncytia formation.

Materials and methods

Cell culture, treatments, plasmids and transfections

Human alveolar type II-like epithelial A549 cells, airway epithelial Calu-3 cells and MRC-5 lung fibroblasts, colorectal adenocarcinoma HCT116 cells, colon carcinoma Caco-2 cells, embryonic kidney 293T cells, and African green monkey kidney Vero E6 cells, murine L929 fibroblasts and bat lung epithelial Tb-1 Lu cells were obtained from ATCC (Manassas, VA, USA). The human Huh7 hepatoma cell line was kindly provided by Massimo Levrero (INSERM, Lyon, France). Cells were grown at 37 °C in a 5% CO₂ atmosphere in RPMI-1640 (Euroclone; A549 cells), DMEM (Euroclone; Vero E6, Huh7, 293T, HTC116 and Caco-2 cells), EMEM (ATCC; MRC-5 and Calu-3 cells) (Lonza; Tb-1 Lu cells) or MEM (Gibco; L929 cells) medium supplemented with 10% fetal calf serum (FCS), 2 mM glutamine and antibiotics. Cell viability was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to MTT formazan conversion assay (Sigma-Aldrich) as described [29].

Nitazoxanide [2-acetyloxy-N-(5-nitro-2-thiazolyl) benzamide, Alinia] and tizoxanide (Romark Laboratories), remdesivir (RDV, MedChemExpress), bortezomib (BTZ, Selleckchem), kifunensine (KFN) (Cayman), ribavirin (RBV), chloroquine (CQ), cycloheximide (CHX), decanoyl-RVKR-CMK (RVKR), tunicamycin (TM), brefeldin A (BFA), castanospermine (CST) and 1-deoxymannojirimicin (DMJ) (Sigma-Aldrich), dissolved in DMSO stock solution (NTZ, TIZ, RDV, RVKR, BTZ, kifunensine, BFA) or aqueous solution (RBV, CQ, CHX, TM, CST, DMJ), were diluted in culture medium and maintained in the medium for the duration of the experiment. Controls received equal amounts of vehicle.

The pCMV3-2019-nCoV-Spike(S1 + S2)-long (SARS-2 S) construct and the C-terminal Flag-tagged pCMV3-2019-nCoV-Spike(S1 + S2)-long-Flag (SARS-2 S-CF), pCMV3-SARS-spike-Flag (SARS S) and pCMV3-Spike (betacoronavirus-2c-EMC2012)-Flag (MERS S), pCMV3-SARS-CoV-2-Spike (S1 + S2)-long(B.1.617.2) (Delta), pCMV3-2019-nCoV-M-Flag (SARS-2 M), pCMV3-2019-nCoV-ENV-Flag (SARS-2 E) and the C-terminal c-Myc-tagged pCMV3-2019-nCoV-NP-Myc (SARS-2 N) vectors were obtained from Sino Biological. The SARS-CoV-2 variants C-terminal Flag-tagged pReceiver-M39 U.K. B.1.1.7 (EX-CoV242-M39, Alpha), South Africa B.1.351 (EX-CoV244-M39-GS, Beta) and Brazil B.1.1.28.1/P.1 (EX-CoV245-M39-GS, Gamma) vectors were obtained from GeneCopoeia. The mutants N501Y, N501Y + E484K and K417N + E484K + N501Y were constructed on the SARS-2 S-CF plasmid; mutations were generated and sequence-validated by Bio-Fab Research (Rome, IT). C-terminal Flag-tagged pCAGGS-SARS2-S-D614 (Addgene plasmid #156420) and pCAGGS-SARS2-S-G614 (Addgene plasmid #156421) vectors were a gift from Hyeryun Choe and Michael Farzan [77]. The pCMV-GFP vector was obtained from Clontech. Transfections were performed using jetPRIME Transfection-Reagent (Polyplus-transfection), according to the manufacturer’s instructions.

Generation of A549 hACE2, 293T hACE2 and Caco-2 hACE2 stable cell lines

Lentiviral particles to generate hACE2 stably expressing cell lines were produced by co-transfection of 293T cells with the VSV-G encoding plasmid [78], the pCMVR 8.74 lentiviral packaging plasmid (a kind gift from R. Piva, University of Turin, Italy) and the pLENTI hACE2 PURO vector (a gift from Raffaele De Francesco, INGM, Milan; Addgene plasmid #155295). At 48 h after transfection, supernatants were collected, filtered through 0.45-mm membranes and used to infect A549, 293T and Caco-2 cells in the presence of 8 µg/ml of polybrene, and then selected with puromycin (1 μg/ml) 72 h after infection. After 10 days in selective medium resistant pools of A549, 293T and Caco-2 cells were obtained. The puromycin selective pressure was removed 24 h before experimental procedures.

Protein analysis, Western blot and endoglycosidase digestion

For analysis of soluble/insoluble proteins whole-cell extracts (WCE) were prepared after lysis in High Salt Buffer (HSB) [79] without DTT. Briefly, cells were washed twice with ice-cold PBS and then lysed in HSB (80 μl). After one cycle of freeze and thaw, and centrifugation at 16,000 × g (10 min at 4 °C), supernatant (soluble) and pellet (insoluble) fractions were collected. Insoluble fractions were solubilized in 60 μl of Buffer-S (50 mM Tris–HCl, pH 8.5, 1% SDS and protease inhibitors) by sonication on ice, using an ultrasonic UP50H processor (Hielscher) (40% amplitude, pulse mode: 6 × 10 s, 15 s pauses) [79].

For Western blot analysis, cell extracts (20 μg/sample) were separated by SDS-PAGE under non-reducing conditions and blotted to a nitrocellulose membrane. Membranes were incubated with the selected antibodies, followed by incubation with peroxidase-labeled anti-rabbit or anti-mouse IgG. Primary and secondary antibodies used are listed in Supplementary Table 1.

For endoglycosidase digestion experiments, samples containing the same amount of protein (50 μg/sample) were processed for endoglycosidase H (Endo-H, NEB) digestion using 5 milliunits Endo-H for 16 h at 37 °C, or for peptide N-glycosidase F (PNGase-F, NEB) digestion using 500 units PNGase-F for 1.5 h at 37 °C, according to the manufacturer’s protocol [28]. Samples were separated by SDS-PAGE under reducing conditions and blotted as described above. Quantitative evaluation of proteins was determined as described [80,81,82]. Spike proteins densitometric analysis and molecular weight determination were carried out using Image Lab Software 6.1, after acquisition on a ChemiDoc XRS + (Bio-Rad). All results shown are representative of at least three independent experiments.

Immunofluorescence microscopy

A549 cells transfected with Flag-tagged SARS-CoV-2 spike or empty vector were grown in 8-well chamber slides (Lab-Tek II) and, after 4 h, were treated with NTZ, TM or vehicle for 16 h. Cells were fixed, permeabilized and processed for immunofluorescence as described [83] using anti-Flag antibodies, followed by decoration with Alexa Fluor 488- or 555-conjugated antibodies (Molecular Probes, Invitrogen). Nuclei were stained with Hoechst 33342 (Molecular Probes, Invitrogen). Images were captured using a ZEISS Axio Observer Inverted Microscope and analyzed using ZEN 3.1 (blue edition) software. For confocal microscopy, images were acquired on Olympus FluoView FV-1000 confocal laser scanning system (Olympus America Inc., Center Valley, PA) and analyzed using Imaris (v6.2) software (Bitplane, Zurich, Switzerland). Images shown in all figures are representative of at least three random fields (scale-bars are indicated).

Cell–cell fusion assay

Two different protocols were used for visualization of syncytia. In the first protocol, Vero E6, Huh7, A549 and A549 hACE2 cells grown in 8-well chamber slides were transfected with Flag-tagged SARS-CoV-2 (SARS-2 S-CF wild type or mutated, pCAGGS-SARS2-S-D614, pCAGGS-SARS2-S-G614) or SARS-CoV spike plasmids or empty vector and, after 4 h, were treated with NTZ or vehicle. After 36 h, cells were processed for immunofluorescence as described above using an anti-Flag antibody. Nuclei were stained with Hoechst. Syncytia images were captured using a ZEISS Axio Observer inverted microscope and analyzed using ZEN 3.1 (blue edition) software. For syncytia formation quantification, the percentage of cells involved in syncytia formation was determined by counting the number of cells containing 3 or more nuclei, compared with the number of total nuclei in transfected cells in the same sample [57]. At least 1.000 nuclei were counted for each sample.

In the donor–target cell fusion assay, 293T cells were co-transfected with plasmids encoding Flag-tagged SARS-CoV-2 S glycoprotein alone or in combination with Flag-tagged SARS-CoV-2 M-glycoprotein and E protein, and c-Myc-tagged N protein together with GFP using Lipofectamine 2000 (Life Technologies), according to the manufacturer’s instructions. For SARS-CoV-2 variants cell fusion assay, 293T cells were co-transfected with the plasmids encoding SARS-CoV-2 S glycoprotein pReceiver-M39 U.K. B.1.1.7 (EX-CoV242-M39) (Alpha), South Africa B.1.351 (EX-CoV244-M39-GS) (Beta), Brazil B.1.1.28.1/P.1 (EX-CoV245-M39-GS) (Gamma) or pCMV3-SARS-CoV-2-Spike (S1 + S2)-long(B.1.617.2) (Delta) together with GFP, as described above. After 4 h, cells were treated with NTZ or vehicle. 293T cells transfected with the GFP-encoding plasmid were used as negative control. Cells were detached with trypsin (0.25%) at 40 h post-transfection and overlaid on an 80% confluent monolayer of target cells [Vero E6 and Huh7 (naturally expressing hACE2 receptors on the membrane surface) or A549 hACE2 (stably transfected with the hACE2 encoding plasmid) cells] at a ratio of approximately one S-expressing cell to three receptor-expressing cells [45]. After 4 h, nuclei were stained with Hoechst. Transmission and fluorescence images were taken using a ZEISS Axio Observer inverted microscope. To measure the extent of cell–cell fusion, the GFP area was delimited, measured using ImageJ software [59], divided by the total cell area and expressed as percentage relative to control.

Images shown in all figures are representative of at least five random fields (scale-bars are indicated). All experiments were done in duplicate and repeated at least three times.

Generation of SARS-CoV-2 S-pseudoviruses

For production of Murine Leukemia Virus (MLV)-based SARS-CoV-2 S-pseudotyped particles, 293T cells grown in 60 mm dishes were co-transfected with the SARS-2 S-CF plasmid encoding the SARS-CoV-2 S protein, the MLV Gag-Pol packaging construct [78] and the MLV transfer vector encoding a luciferase reporter (PTG-Luciferase) [78]. For production of lentiviral SARS-CoV-2 S-pseudotyped particles, 293T cells were co-transfected with the SARS-2 S-CF plasmid [or alternatively, the pCAGGS-SARS2-S-D614, pCAGGS-SARS2-S-G614, pReceiver-M39 U.K. B.1.1.7 (EX-CoV242-M39) (Alpha), South Africa B.1.351 (EX-CoV244-M39-GS) (Beta), Brazil B.1.1.28.1/P.1 (EX-CoV245-M39-GS) (Gamma) or pCMV3-SARS-CoV-2-Spike (S1 + S2)-long(B.1.617.2) (Delta) plasmids], the pCMVR 8.74 lentiviral packaging plasmid and the pLenti CMV Puro LUC or pLenti CMV Puro GFP vectors. pLenti CMV Puro LUC (Addgene plasmid #17477) and pLenti CMV Puro GFP (Addgene plasmid #17448) vectors were a gift from Eric Campeau and Paul Kaufman [84]. Transfections were performed using Lipofectamine 2000 (Life Technologies), according to the manufacturer’s instructions. After 5 h, cells were washed twice with medium and treated with different concentrations of NTZ or vehicle. At 48 h after transfection, supernatants containing the viral particles were collected and filtered through 0.45 mm membranes. Pseudoviruses were purified using PEG Virus Precipitation Kit (Abcam), resuspended in 100 µl of virus re-suspension solution and then frozen at − 80 °C until use. After collection of viral particles, the monolayers of 293T-producing cells were lysed and analyzed for S protein levels as described above.

Pseudovirus entry assays

Vero E6, Calu-3, Caco-2, Caco-2 hACE2 and 293T hACE2 cells were plated at a density of 2 × 10⁴ cells/well in 96-well white clear-bottom plates (Costar). After 18 h, 0.1 ml of DMEM containing 5% FCS and 8 μg/ml polybrene was added to each well and cells were incubated for 30 min. The medium was then removed and the pseudovirus suspension (50 µl: 5 µl of purified pseudovirus stock + 45 µl of DMEM containing 5% FCS) was added; after 24 h, 0.05 ml of DMEM 5% FCS was added to each well. Luciferase activity (Relative Luciferase Units or RLU) was detected at 72 h post-infection using Bright-Glo Luciferase Assay System Kit (Promega) in a Microplate Luminometer (Wallac-Perkin Elmer).

All experiments were performed in triplicates, and repeated at least three times.

Antiviral activity assay

To determine the antiviral activity of tizoxanide, Vero E6 cells were infected with SARS-CoV-2 (SARS-CoV-2/England/2/2020) virus for 2 h, and then treated with a three-fold serial dilution of compound ranging from 20 to 0.01 μM. Antiviral activity was determined at 24 h using an immunofluorescence-based assay. Briefly, cells were fixed, permeabilized and stained with an antibody recognizing SARS-CoV-2 spike protein (GeneTex GTX632604). The primary antibody was detected with an Alexa-488 conjugate secondary antibody (Life Technologies, A11001), and nuclei were stained with Hoechst. Images were acquired on an Opera Phenix high content confocal microscope (Perkin Elmer) using a 10X objective (9 images per well, covering approx. 2/3 of the well), and percentages of infection were calculated using Columbus software (infected cells/total cells × 100). The percentage of inhibition of SARS-CoV-2 infection was normalized to the internal controls (100% inhibition is derived from the average of the untreated uninfected control and 0% inhibition is derived from the average of the untreated infected control). Cell viability was determined by MTT assay [29]. Cytotoxicity values were normalized to the internal control (untreated cells, 100% viability). Tizoxanide antiviral activity assays against SARS-CoV-2 were performed by Virology Research Services Ltd (UK).

Statistical analysis

Statistical analysis was performed using the Student’s t test for unpaired data or one-way ANOVA test (Prism 5.0 software, GraphPad). Data are expressed as the mean ± SD of samples derived from at least three biological repeats and P values ≤ 0.05 were considered significant. All the results shown are representative of at least three independent experiments, each in duplicate or triplicate.

Data availability statement

Data will be made available on reasonable request.

Change history

30 July 2022
Missing Open Access funding information has been added in the Funding Note

References

Cui J, Li F, Shi ZL (2019) Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 17:181–192
Article CAS PubMed Google Scholar
Kim D, Lee JY, Yang JS, Kim JW, Kim VN, Chang H (2020) The architecture of SARS-CoV-2 transcriptome. Cell 181:914-921.e10
Article CAS PubMed PubMed Central Google Scholar
Fung TS, Liu DX (2019) Human Coronavirus: host-pathogen interaction. Annu Rev Microbiol 73:529–557
Article CAS PubMed Google Scholar
de Wit E, van Doremalen N, Falzarano D, Munster VJ (2016) SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 14:523–534
Article PubMed PubMed Central CAS Google Scholar
Hu B, Guo H, Zhou P, Shi ZL (2021) Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 19:141–154
Article CAS PubMed Google Scholar
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC (2020) Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19): a review. JAMA 324:782–793
Article CAS PubMed Google Scholar
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D (2020) Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181:281-292.e6
Article CAS PubMed PubMed Central Google Scholar
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:271-280.e8
Article CAS PubMed PubMed Central Google Scholar
Cai Y, Zhang J, Xiao T, Peng H, Sterling SM, Walsh RM Jr, Rawson S, Rits-Volloch S, Chen B (2020) Distinct conformational states of SARS-CoV-2 spike protein. Science 369:1586–1592
Article CAS PubMed Google Scholar
Santopolo S, Riccio A, Santoro MG (2020) The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy. Biochem Biophys Res Commun 538:80–87
Article PubMed PubMed Central CAS Google Scholar
Gong Y, Qin S, Dai L, Tian Z (2021) The glycosylation in SARS-CoV-2 and its receptor ACE2. Signal Transduct Target Ther 6:396
Article CAS PubMed PubMed Central Google Scholar
Sicari D, Chatziioannou A, Koutsandreas T, Sitia R, Chevet E (2020) Role of the early secretory pathway in SARS-CoV-2 infection. J Cell Biol 219:e202006005
Article CAS PubMed PubMed Central Google Scholar
Alexander S, Elder JH (1984) Carbohydrate dramatically influences immune reactivity of antisera to viral glycoprotein antigens. Science 226:1328–1330
Article CAS PubMed Google Scholar
Braakman I, van Anken E (2000) Folding of viral envelope glycoproteins in the endoplasmic reticulum. Traffic 1:533–539
Article CAS PubMed PubMed Central Google Scholar
Hoffmann M, Kleine-Weber H, Pöhlmann S (2020) A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell 78:779-784.e5
Article CAS PubMed PubMed Central Google Scholar
Jackson CB, Farzan M, Chen B, Choe H (2022) Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol 23:3–20
Article CAS PubMed Google Scholar
Horimoto T, Kawaoka Y (2005) Influenza: lessons from past pandemics, warnings from current incidents. Nat Rev Microbiol 3:591–600
Article CAS PubMed Google Scholar
Krause PR, Fleming TR, Longini IM, Peto R, Briand S, Heymann DL, Beral V, Snape MD, Rees H, Ropero AM et al (2021) SARS-CoV-2 variants and vaccines. N Engl J Med 385:179–186
Article CAS PubMed Google Scholar
Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF (2021) Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol 21:626–636
Article CAS PubMed PubMed Central Google Scholar
Dong Y, Dai T, Wang B, Zhang L, Zeng LH, Huang J, Yan H, Zhang L, Zhou F (2021) The way of SARS-CoV-2 vaccine development: success and challenges. Signal Transduct Target Ther 6:387
Article CAS PubMed PubMed Central Google Scholar
Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, Muecksch F, Rutkowska M, Hoffmann HH, Michailidis E et al (2020) Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife 9:e61312
Article CAS PubMed PubMed Central Google Scholar
Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, Staropoli I, Porrot F, Planchais C, Buchrieser J, Rajah MM, Bishop E et al (2021) Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med 27:917–924
Article CAS PubMed Google Scholar
Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, Ludden C, Reeve R, Rambaut A et al (2021) SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 19:409–424
Article CAS PubMed PubMed Central Google Scholar
Rossignol JF, Ayoub A, Ayers MS (2001) Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 184:381–384
Article CAS PubMed Google Scholar
Rossignol JF, Kabil SM, el-Gohary Y, Younis AM (2006) Effect of nitazoxanide in diarrhea and enteritis caused by Cryptosporidium species. Clin Gastroenterol Hepatol 4:320–324
Article CAS PubMed Google Scholar
Rossignol JF (2014) Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res 110:94–103
Article CAS PubMed PubMed Central Google Scholar
Li G, De Clercq E (2020) Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 19:149–150
Article PubMed CAS Google Scholar
Rossignol JF, La Frazia S, Chiappa L, Ciucci A, Santoro MG (2009) Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem 284:29798–29808
Article CAS PubMed PubMed Central Google Scholar
Piacentini S, La Frazia S, Riccio A, Pedersen JZ, Topai A, Nicolotti O, Rossignol JF, Santoro MG (2018) Nitazoxanide inhibits paramyxovirus replication by targeting the Fusion protein folding: role of glycoprotein-specific thiol oxidoreductase ERp57. Sci Rep 8:10425
Article PubMed PubMed Central CAS Google Scholar
Korba BE, Montero AB, Farrar K, Gaye K, Mukerjee S, Ayers MS, Rossignol JF (2008) Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res 77:56–63
Article CAS PubMed Google Scholar
La Frazia S, Ciucci A, Arnoldi F, Coira M, Gianferretti P, Angelini M, Belardo G, Burrone OR, Rossignol JF, Santoro MG (2013) Thiazolides, a new class of antiviral agents effective against rotavirus infection, target viral morphogenesis, inhibiting viroplasm formation. J Virol 87:11096–11106
Article PubMed PubMed Central CAS Google Scholar
Rossignol JF, Abu-Zekry M, Hussein A, Santoro MG (2006) Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial. Lancet 368:124–129
Article CAS PubMed Google Scholar
Haffizulla J, Hartman A, Hoppers M, Resnick H, Samudrala S, Ginocchio C, Bardin M, Rossignol JF, US Nitazoxanide Influenza Clinical Study Group (2014) Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis 14:609–618
Article CAS PubMed PubMed Central Google Scholar
Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB (2009) Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 136:856–862
Article CAS PubMed Google Scholar
Cao J, Forrest JC, Zhang X (2015) A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs. Antiviral Res 114:1–10
Article CAS PubMed Google Scholar
Rossignol JF (2016) Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health 9:227–230
Article PubMed PubMed Central Google Scholar
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269–271
Article CAS PubMed PubMed Central Google Scholar
Son J, Huang S, Zeng Q, Bricker TL, Case JB, Zhou J, Zang R, Liu Z, Chang X, Harastani HH et al (2021) JIB-04 has broad-spectrum antiviral activity and inhibits SARS-CoV-2 replication and coronavirus pathogenesis. bioRxiv. https://doi.org/10.1101/2020.09.24.312165
Article PubMed PubMed Central Google Scholar
Rocco PRM, Silva PL, Cruz FF, Melo-Junior MAC, Tierno PFGMM, Moura MA, De Oliveira LFG, Lima CC, Dos Santos EA, Junior WF et al (2021) Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial. Eur Respir J 58:2003725
Article CAS PubMed PubMed Central Google Scholar
Silva M, Espejo A, Pereyra ML, Lynch M, Thompson M, Taconelli H, Baré P, Pereson MJ, Garbini M, Crucci P et al (2021) Efficacy of Nitazoxanide in reducing the viral load in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel group, pilot study. medRxiv. https://doi.org/10.1101/2021.03.03.21252509
Article PubMed PubMed Central Google Scholar
Blum VF, Cimerman S, Hunter JR, Tierno P, Lacerda A, Soeiro A, Cardoso F, Bellei NC, Maricato J, Mantovani N et al (2021) Nitazoxanide superiority to placebo to treat moderate COVID-19 - A Pilot prove of concept randomized double-blind clinical trial. EClinicalMedicine 37:100981
Article PubMed PubMed Central Google Scholar
Rossignol JF, Bardin MC, Fulgencio J, Mogelnicki D, Bréchot C, for the Vanguard Study Group (2022) A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19. eClinicalMedicine 45:101310
Article PubMed PubMed Central Google Scholar
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS (2020) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367:1260–1263
Article CAS PubMed PubMed Central Google Scholar
Li T, Zheng Q, Yu H, Wu D, Xue W, Zhang Y, Huang X, Zhou L, Zhang Z, Zha Z et al (2020) Characterization of the SARS-CoV-2 spike in an early prefusion conformation. bioRxiv. https://doi.org/10.1101/2020.03.16.994152
Article PubMed PubMed Central Google Scholar
Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J et al (2020) Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 11:1620
Article CAS PubMed PubMed Central Google Scholar
Millet JK, Whittaker GR (2014) Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc Natl Acad Sci USA 111:15214–15219
Article CAS PubMed PubMed Central Google Scholar
Plante JA, Liu Y, Liu J, Xia H, Johnson BA, Lokugamage KG, Zhang X, Muruato AE, Zou J, Fontes-Garfias CR et al (2020) Spike mutation D614G alters SARS-CoV-2 fitness. Nature 592:116–121
Article PubMed PubMed Central CAS Google Scholar
Manasanch EE, Orlowski RZ (2017) Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol 14:417–433
Article CAS PubMed PubMed Central Google Scholar
Morito D, Nagata K (2015) Pathogenic hijacking of ER-associated degradation: is ERAD flexible? Mol Cell 59:335–344
Article CAS PubMed Google Scholar
Delmas B, Laude H (1991) Carbohydrate-induced conformational changes strongly modulate the antigenicity of coronavirus TGEV glycoproteins S and M. Virus Res 20:107–120
Article CAS PubMed PubMed Central Google Scholar
Xu C, Ng DTW (2015) Glycosylation-directed quality control of protein folding. Nat Rev Mol Cell Biol 16:742–752
Article CAS PubMed Google Scholar
Ohuchi R, Ohuchi M, Garten W, Klenk HD (1997) Oligosaccharides in the stem region maintain the influenza virus hemagglutinin in the metastable form required for fusion activity. J Virol 71:3719–3725
Article CAS PubMed PubMed Central Google Scholar
Mishin VP, Novikov D, Hayden FG, Gubareva LV (2005) Effect of hemagglutinin glycosylation on influenza virus susceptibility to neuraminidase inhibitors. J Virol 79:12416–12424
Article CAS PubMed PubMed Central Google Scholar
Boson B, Legros V, Zhou B, Siret E, Mathieu C, Cosset FL, Lavillette D, Denolly S (2021) The SARS-CoV-2 envelope and membrane proteins modulate maturation and retention of the spike protein, allowing assembly of virus-like particles. J Biol Chem 296:100111
Article CAS PubMed Google Scholar
Yang Q, Hughes TA, Kelkar A, Yu X, Cheng K, Park S, Huang WC, Lovell JF, Neelamegham S (2020) Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration. Elife 9:e61552
Article CAS PubMed PubMed Central Google Scholar
Ren X, Glende J, Al-Falah M, de Vries V, Schwegmann-Wessels C, Qu X, Tan L, Tschernig T, Deng H, Naim HY et al (2006) Analysis of ACE2 in polarized epithelial cells: surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus. J Gen Virol 87:1691–1695
Article CAS PubMed Google Scholar
Belouzard S, Chu VC, Whittaker GR (2009) Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc Natl Acad Sci USA 106:5871–5876
Article CAS PubMed PubMed Central Google Scholar
Bussani R, Schneider E, Zentilin L, Collesi C, Ali H, Braga L, Volpe MC, Colliva A, Zanconati F, Berlot G et al (2020) Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology. EBioMedicine 61:103104
Article PubMed PubMed Central Google Scholar
Buchrieser J, Dufloo J, Hubert M, Monel B, Planas D, Rajah MM, Planchais C, Porrot F, Guivel-Benhassine F, Van der Werf S et al (2020) Syncytia formation by SARS-CoV-2-infected cells. EMBO J 39:e106267
Article CAS PubMed PubMed Central Google Scholar
Plescia CB, David EA, Patra D, Sengupta R, Amiar S, Su Y, Stahelin RV (2021) SARS-CoV-2 viral budding and entry can be modeled using BSL-2 level virus-like particles. J Biol Chem 296:100103
Article CAS PubMed Google Scholar
Bracquemond D, Muriaux D (2021) Betacoronavirus assembly: clues and perspectives for elucidating SARS-CoV-2 particle formation and egress. MBio 12:e0237121
Article PubMed Google Scholar
Robson F, Khan KS, Le TK, Paris C, Demirbag S, Barfuss P, Rocchi P, Ng WL (2020) Coronavirus RNA proofreading: molecular basis and therapeutic targeting. Mol Cell 79:710–727
Article CAS PubMed PubMed Central Google Scholar
Hiscox JA, Khoo SH, Stewart JP, Owen A (2021) Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance? J Antimicrob Chemother 76:2230–2233
Article CAS PubMed PubMed Central Google Scholar
Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, Hengartner N, Giorgi EE, Bhattacharya T, Foley B et al (2020) Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182:812-827.e19
Article CAS PubMed PubMed Central Google Scholar
Edridge AWD, Kaczorowska J, Hoste ACR, Bakker M, Klein M, Loens K, Jebbink MF, Matser A, Kinsella CM, Rueda P et al (2020) Seasonal coronavirus protective immunity is short-lasting. Nat Med 26:1691–1693
Article CAS PubMed Google Scholar
Santoro MG, Carafoli E (2020) Remdesivir: from Ebola to COVID-19. Biochem Biophys Res Commun 538:145–150
Article PubMed PubMed Central CAS Google Scholar
Wahl A, Gralinski LE, Johnson CE, Yao W, Kovarova M, Dinnon KH 3rd, Liu H, Madden VJ, Krzystek HM, De C et al (2021) SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 591:451–457
Article CAS PubMed PubMed Central Google Scholar
Theuerkauf SA, Michels A, Riechert V, Maier TJ, Flory E, Cichutek K, Buchholz CJ (2021) Quantitative assays reveal cell fusion at minimal levels of SARS-CoV-2 spike protein and fusion-from-without. iScience 24:102170
Article CAS PubMed PubMed Central Google Scholar
Griffin DE (2020) Measles virus persistence and its consequences. Curr Opin Virol 41:46–51
Article CAS PubMed PubMed Central Google Scholar
Compton AA, Schwartz O (2017) They might me giants: does syncytium formation sink or spread HIV infection? PLoS Pathog 13:e1006099
Article PubMed PubMed Central CAS Google Scholar
Sattentau Q (2008) Avoiding the void: cell-to-cell spread of human viruses. Nat Rev Microbiol 6:815–826
Article CAS PubMed Google Scholar
Ferren M, Horvat B, Mathieu C (2019) Measles encephalitis: towards new therapeutics. Viruses 11:1017
Article CAS PubMed Central Google Scholar
Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY (2020) Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol 15:700–704
Article CAS PubMed PubMed Central Google Scholar
Rockx B, Kuiken T, Herfst S, Bestebroer T, Lamers MM, Oude Munnink BB, de Meulder D, van Amerongen G, van den Brand J, Okba NMA et al (2020) Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science 368:1012–1015
Article CAS PubMed PubMed Central Google Scholar
Cattin-Ortolá J, Welch L, Maslen SL, Skehel JM, Papa G, James LC, Munro S (2021) Sequences in the cytoplasmic tail of SARS-CoV-2 spike facilitate expression at the cell surface and syncytia formation. Nat Commun 12:5333
Article PubMed PubMed Central CAS Google Scholar
Sanders DW, Jumper CC, Ackerman PJ, Bracha D, Donlic A, Kim H, Kenney D, Castello-Serrano I, Suzuki S, Tamura T et al (2021) SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation. Elife 10:e65962
Article CAS PubMed PubMed Central Google Scholar
Zhang L, Jackson CB, Mou H, Ojha A, Peng H, Quinlan BD, Rangarajan ES, Pan A, Vanderheiden A, Suthar MS et al (2020) SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun 11:6013
Article CAS PubMed PubMed Central Google Scholar
Millet JK, Whittaker GR (2016) Murine leukemia virus (MLV)-based coronavirus spike-pseudotyped particle production and infection. Bio Protoc 6:e2035
Article PubMed Google Scholar
Coccia M, Rossi A, Riccio A, Trotta E, Santoro MG (2017) Human NF-κB repressing factor acts as a stress-regulated switch for ribosomal RNA processing and nucleolar homeostasis surveillance. Proc Natl Acad Sci USA 114:1045–1050
Article CAS PubMed PubMed Central Google Scholar
Santoro MG, Jaffe BM, Esteban M (1983) Prostaglandin A inhibits the replication of vesicular stomatitis virus: effect on virus glycoprotein. J Gen Virol 64:2797–2801
Article CAS PubMed Google Scholar
Santoro MG, Amici C, Elia G, Benedetto A, Garaci E (1989) Inhibition of virus protein glycosylation as the mechanism of the antiviral action of prostaglandin A in Sendai virus-infected cells. J Gen Virol 70:789–800
Article CAS PubMed Google Scholar
Pizzato Scomazzon S, Riccio A, Santopolo S, Lanzilli G, Coccia M, Rossi A, Santoro MG (2019) The zinc-finger AN1-type domain 2a gene acts as a regulator of cell survival in human melanoma: role of E3-ligase cIAP2. Mol Cancer Res 17:2444–2456
Article PubMed Google Scholar
Santopolo S, Riccio A, Rossi A, Santoro MG (2021) The proteostasis guardian HSF1 directs the transcription of its paralog and interactor HSF2 during proteasome dysfunction. Cell Mol Life Sci 78:1113–1129
Article CAS PubMed Google Scholar
Campeau E, Ruhl VE, Rodier F, Smith CL, Rahmberg BL, Fuss JO, Campisi J, Yaswen P, Cooper PK, Kaufman PD (2009) A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS ONE 4:e6529
Article PubMed PubMed Central CAS Google Scholar
Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, Li F (2020) Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci USA 117:11727–11734
Article CAS PubMed PubMed Central Google Scholar

Download references

Acknowledgements

The authors thank Massimo Levrero (INSERM U1052, Lyon, France) for providing the Huh7 hepatoma cell line.

Funding

Open access funding provided by Università degli Studi di Roma Tor Vergata within the CRUI-CARE Agreement. This research was supported by Romark Laboratories LC, Tampa, Florida, and by a grant from the Italian Ministry of University and Scientific Research (PRIN project N 2010PHT9NF-006).

Author information

Anna Riccio and Silvia Santopolo have contributed equally to this work.

Authors and Affiliations

Department of Biology, University of Rome Tor Vergata, Rome, Italy
Anna Riccio, Silvia Santopolo, Sara Piacentini & M. Gabriella Santoro
Institute of Translational Pharmacology, CNR, Rome, Italy
Antonio Rossi & M. Gabriella Santoro
Romark Institute of Medical Research, Tampa, FL, USA
Jean-Francois Rossignol

Authors

Anna Riccio
View author publications
You can also search for this author in PubMed Google Scholar
Silvia Santopolo
View author publications
You can also search for this author in PubMed Google Scholar
Antonio Rossi
View author publications
You can also search for this author in PubMed Google Scholar
Sara Piacentini
View author publications
You can also search for this author in PubMed Google Scholar
Jean-Francois Rossignol
View author publications
You can also search for this author in PubMed Google Scholar
M. Gabriella Santoro
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

AR, SS and SP performed the analysis of protein synthesis, maturation and intracellular localization; A. Rossi performed the pseudovirus studies; AR and SS conducted the cell–cell fusion study; MGS and JFR designed the study; MGS, AR and SS wrote the manuscript. All the authors contributed to the interpretation of the data and approve the content of the manuscript.

Corresponding author

Correspondence to M. Gabriella Santoro.

Ethics declarations

Conflict of interest

Financial support for this study was in part provided by Romark Laboratories LC, the company that owns the intellectual property rights related to nitazoxanide. JF Rossignol is an employee and stockholder of Romark Laboratories, LC.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent to publish

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 78209 KB)

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Riccio, A., Santopolo, S., Rossi, A. et al. Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by nitazoxanide: an effect independent of spike variants emergence. Cell. Mol. Life Sci. 79, 227 (2022). https://doi.org/10.1007/s00018-022-04246-w

Download citation

Received: 05 January 2022
Revised: 03 March 2022
Accepted: 11 March 2022
Published: 07 April 2022
DOI: https://doi.org/10.1007/s00018-022-04246-w

Keywords

Use our pre-submission checklist

Avoid common mistakes on your manuscript.

Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by nitazoxanide: an effect independent of spike variants emergence

Abstract

Similar content being viewed by others

Spike mutation D614G alters SARS-CoV-2 fitness

Imatinib inhibits SARS-CoV-2 infection by an off-target-mechanism

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Introduction

Results

Characterization of furin-dependent cleavage of SARS-CoV-2 S protein in human lung cells

Nitazoxanide alters SARS-CoV-2 S protein biogenesis in human cells

Nitazoxanide does not affect SARS-CoV-2 spike stability and oligomerization, but impairs its maturation at an Endo-H-sensitive stage

Nitazoxanide treatment prevents SARS-CoV-2 S pseudovirions infection

Nitazoxanide inhibits SARS-CoV-2 S-mediated cell–cell fusion and syncytia formation

Nitazoxanide inhibits the fusogenic activity of SARS-CoV-2 spike variants

Discussion

Materials and methods

Cell culture, treatments, plasmids and transfections

Generation of A549 hACE2, 293T hACE2 and Caco-2 hACE2 stable cell lines

Protein analysis, Western blot and endoglycosidase digestion

Immunofluorescence microscopy

Cell–cell fusion assay

Generation of SARS-CoV-2 S-pseudoviruses

Pseudovirus entry assays

Antiviral activity assay

Statistical analysis

Data availability statement

Change history

30 July 2022

References

Acknowledgements

Funding

Author information

Authors and Affiliations

Contributions

Corresponding author

Ethics declarations

Conflict of interest

Ethics approval

Consent to participate

Consent to publish

Additional information

Publisher's Note

Supplementary Information

Supplementary file1 (PDF 78209 KB)

Rights and permissions

About this article

Cite this article

Share this article

Keywords

Search

Navigation